Stephens upgraded shares of Fennec Pharmaceuticals (TSE:FRX – Free Report) to a strong-buy rating in a research report sent to investors on Monday morning,Zacks.com reports. Fennec Pharmaceuticals ...

Stephens upgraded shares of Fennec Pharmaceuticals (NASDAQ:FENC – Free Report) to a strong-buy rating in a research report sent to investors on Monday morning,Zacks.com reports. Other research ...

Stephens initiated coverage of Fennec (FENC) with an Overweight rating and $15 price target The firm is adding to its Biotechnology research coverage with a focus on targeted protein degradation, or ...

Fennec Pharmaceuticals reported solid third-quarter financial results with $7.0 million in net product sales, bolstered by strategic investments in the Adolescent and Young Adult market. The company ...

Fennec Pharmaceuticals (TSE:FRX) has released an update. Fennec Pharmaceuticals reported solid third-quarter financial results with $7.0 million in net product sales, bolstered by strategic ...

Revenue missed analyst estimates by 22%. Earnings per share (EPS) also missed analyst estimates by 133%. Looking ahead, ...

已保存。查看收藏列表。 在充满挑战的市场环境中，Fennec Pharmaceuticals Inc. (FENC)股票触及52周低点，达到4.07美元的价格水平。这一下跌反映出与之前估值相比的显著收缩，与过去更为乐观的交易时期形成鲜明对比。在过去一年中，Fennec Pharma的股票价值大幅下降了 ...

Analysts expect adjusted earnings to reach $-0.040 per share for the current fiscal year. Fennec Pharmaceuticals Inc. does not currently pay a dividend. AAII’s proprietary stock grades come with A+ ...

Q3 2024 Earnings Call Transcript November 9, 2024 Operator: Good morning, ladies and gentlemen, and welcome to Fennec ...

Joining me from Fennec this morning is our Chief Executive ... G&A increases year-over-year can be attributed to noncash stock compensation related both to the separation of our CEO and our ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...